NIH Panel Releases Update to COVID-19 Treatment Guidelines
February 25, 2022
The COVID-19 Treatment Guidelines Panel (the Panel) has released a new version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Important changes in the Guidelines include:
- Updated recommendations on therapeutic management of hospitalized adults with COVID-19.
- Addition of a new section on therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with a discussion of multisystem inflammatory syndrome in adults [MIS-A]).
- New recommendations regarding antiviral drugs that are approved, authorized, or under evaluation for the treatment of COVID-19, including use of ritonavir-boosted nirmatrelvir, remdesivir, and molnupiravir in nonhospitalized patients with mild to moderate COVID-19 who are at high risk of disease progression.
- A new section on use of ritonavir-boosted nirmatrelvir (Paxlovid).
- Recommendations for using remdesivir in nonhospitalized patients.
- A new section on use of molnupiravir that incorporates information from the Panel’s statement on therapies for high-risk, nonhospitalized patients.
- Addition of ritonavir-boosted nirmatrelvir and molnupiravir to Table 2f with updates to the remdesivir entry that incorporate recent FDA labeling changes.
- Updated information on use of antithrombotic therapy in patients with COVID-19, including a new clinical data table that describes the randomized controlled trials that had the greatest impact on the Panel’s recommendations.
For complete details on these updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.